{
    "nctId": "NCT00107276",
    "briefTitle": "S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer",
    "officialTitle": "Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 112,
    "primaryOutcomeMeasure": "Response Rate (Complete and Partial, Confirmed and Unconfirmed)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed stage IV breast cancer\n\n  * Metastatic disease (M1) OR multiple sites of new disease that is clinically obvious metastatic disease (i.e., multiple sites of new osseous disease)\n* Meets 1 of the following criteria:\n\n  * Measurable disease\n  * Non-measurable disease\n\n    * MUC-1 antigen level \\> 2 times upper limit of normal AND level has increased by 1.5 times\n* Must have documented MUC-1 antigen level\n\n  * Either cancer antigen (CA) 15-3 or CA 27-29 allowed\n* Must have received at least 1 prior hormonal therapy for metastatic disease (estogen receptor-positive patients only)\n* No symptomatic brain or CNS metastases\n\n  * Previously treated brain or CNS metastasis allowed provided radiotherapy was completed \u2265 8 weeks before study entry\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Zubrod 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* No known existing uncontrolled coagulopathy\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Creatinine clearance \\> 40 mL/min\n\nCardiovascular\n\n* No congestive heart failure\n* No symptomatic coronary artery disease\n* No cardiac arrhythmia not well controlled with medication\n* No myocardial infarction within the past 12 months\n* No other clinically significant cardiac disease\n\nGastrointestinal\n\n* Able to take oral medication\n* No uncontrolled nausea, vomiting, or diarrhea\n* No lack of physical integrity of the upper gastrointestinal tract\n* No malabsorption syndrome\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No active infection requiring systemic therapy\n* No prior severe reaction to fluoropyrimidines\n* No known sensitivity to fluorouracil\n* No known dihydropyrimidine dehydrogenase deficiency\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No concurrent immunotherapy or biologic therapy for breast cancer\n* No concurrent gene therapy for breast cancer\n* No concurrent filgrastim (G-CSF)\n\nChemotherapy\n\n* At least 14 days since prior chemotherapy and recovered\n* No more than 2 prior chemotherapy regimens for metastatic disease\n* No prior capecitabine for metastatic disease\n* No prior oral cyclophosphamide for metastatic disease\n\n  * Prior IV cyclophosphamide allowed\n* No other concurrent chemotherapy for breast cancer\n\nEndocrine therapy\n\n* See Disease Characteristics\n* No concurrent hormonal therapy for breast cancer\n\nRadiotherapy\n\n* See Disease Characteristics\n* At least 14 days since prior radiotherapy to non-CNS disease sites and recovered\n* No concurrent radiotherapy for breast cancer\n\nSurgery\n\n* Not specified\n\nOther\n\n* Concurrent bisphosphonates allowed\n* No concurrent full-dose warfarin\n\n  * Concurrent prophylactic warfarin (\u2264 1 mg/day) to maintain port patency allowed\n* No other concurrent antineoplastic therapy for breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}